News|Articles|November 17, 2026

Atopic Dermatitis Escalation Stalls on Payer Rules, Thin Tracking

Fact checked by: Ashley Gallagher, MA
Listen
0:00 / 0:00

Key Takeaways

  • Body surface area is captured primarily to meet step-therapy criteria, while limited PRO integration and billing-optimized EHR workflows impede recognition of underreported symptoms and true disease burden.
  • Disparities in assessment and access affect young adults, patients with skin of color, and older Asian patients; pediatric families face specialist delays and persistent topical underuse due to steroid concerns.
SHOW MORE

San Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy teams and dashboards.

Appropriate escalation of atopic dermatitis treatment is slowed by barriers such as payer step requirements, billing-driven documentation, and a lack of tracking once patients start biologics, said participants at The American Journal of Managed Care®’s Population Health Roundtable in San Francisco, California. They pointed to pharmacy teams, patient-reported outcome tools, and simple dashboards as realistic near-term fixes. Names of some panelists have been withheld at their request.

How Is Disease Burden Being Captured?

Most participants said they record body surface area because step therapy requirements ask for it, not because it captures how patients are doing. Validated patient-reported scores are rarely built into visit workflows, which makes it hard during a short visit to spot patients who underreport their suffering. Describing the electronic health record, one dermatologist said, “It’s optimized for billing; it’s not necessarily optimized for how good of care we’re taking of people.”

Participants said young adults, patients with skin of color, and middle-aged and older Asian patients may be undertreated, and that pediatric families face long waits for dermatology and allergy visits. One participant noted that patients with skin of color have a high burden of disease but are graded lower on severity. In general, socioeconomic burdens are a barrier to access, but these and other issues are not documented as much as body surface area.

What Determines Which Therapy Patients Get?

Several participants said their health systems had no defined atopic dermatitis pathway, so escalation varies by clinician, and referrals arrive unpredictably, often from patients who have tried little and waited 6 months. Topical therapy also remains underused in children because of parental steroid concerns, and one participant who treats young children estimated that half or more of those patients arrive treatment naive.

Others questioned whether a defined pathway, such as one used at an integrated health system, simply substitutes for step therapy. The gap between the number of dermatologists available and the demand is another reason why defined pathways probably aren’t in place, one person suggested.

Guidelines can help justify treatment choices, but they ultimately are not the final say on which therapy a patient receives. “Everything, at the end of the day, is limited by what the insurance will approve for the patient,” said another dermatologist. Participants called Medicare the hardest barrier because patients there often cannot get assistance. Responses to denials differed: one participant always appeals, noting that some denials appear automated, while another rarely appeals and moves to a covered drug.

Escalation is increasingly patient-driven, participants said, so expectation-setting matters: itch usually improves before the rash. Patients and parents also raise long-term safety concerns after online searches and news coverage of lawsuits.

How Pharmacy Teams Are Closing Gaps

An in-house specialty pharmacy was the most praised operational lever. Participants said it handles prior authorizations and can prompt clinicians when refills and labs are due. “They are capable of doing a lot of things for us if we had systems to do that proactively on our side,” said one of the participants.

That visibility ends when prescriptions transfer to outside mail-order pharmacies, participants said. Patients can fall through the cracks, and clinicians learn of lapses through serial automated refill requests for patients they have already asked to schedule a visit. One participant has begun discharging stable patients to primary care for annual refills, relying on pharmacy support, so appointments go to patients who need them.

Ways to Improve Long-Term Follow-Up

Clinicians cannot easily see who is on which biologic, and no team follows patients after initiation. “I don’t know of a way to query which of my patients are on Dupixent [dupilumab; Sanofi and Regeneron],” one participant said.

Near-term ideas included a dashboard of patients by biologic and last visit, automated patient-reported outcomes, alerts showing which biologics a patient’s plan covers at the time of ordering, and order sets that bundle a year of lab orders with a pharmacy alert. Participants also floated a shared immune-mediated inflammatory disease clinic with a common care coordinator and a multidisciplinary allergy and dermatology clinic for children.

Several cautioned that none of it will happen without protected time, authority, and dedicated informatics support, since clinicians now work as individual operators with little incentive for system change.


Related to this article